19 batches of Maiden Pharma’s albendazole tablets fail quality tests: The Tribune India | Tech Reddy


Tribune News Service

Bhartesh Singh Thakur

Chandigarh, October 31

19 batches of albendazole tablets manufactured by Sonepat-based Maiden Pharmaceuticals failed quality tests under scrutiny for tainted cough syrup that killed more than 66 children in Gambia.

Haryana Medical Services Corporation Ltd (HMSCL) procured these tablets for government hospitals and dispensaries. These are used to treat parasitic infections. Batches (August/September 2022 and Expiry date 2024) quality tested at private panel laboratory, failed “Pharmacopoeia Commission of India-2018 dissolution test parameter”. A show-cause notice must be issued by HMSCL to blacklist a firm. A command of speech is also required.

The Tribune, in a report on October 22, said that HMSCL has blocked orders from Maiden Pharmaceuticals and stopped the use of medicines and syrups purchased last year.

Health Minister Anil Vij said that the State Narcotics Controller has taken the samples to be tested in the state laboratory. According to him, the government is consulting the Advocate General for further action. The World Health Organization (WHO) issued a warning on October 5 after four cough syrups manufactured by Maiden Pharmaceuticals were found to contain unacceptable levels of diethylene glycol and ethylene glycol.



Source link